Annals of Surgical Oncology

, Volume 20, Issue 11, pp 3582–3590 | Cite as

Liver Transplantation in Patients with Hepatitis B Virus-Related Hepatocellular Carcinoma: The Influence of Viral Characteristics on Clinical Outcome

  • Ting-Jung Wu
  • Kun-Ming Chan
  • Hong-Shiue Chou
  • Chen-Fang Lee
  • Tsung-Han Wu
  • Tse-Ching Chen
  • Chau-Ting Yeh
  • Wei-Chen Lee
Hepatobiliary Tumors

Abstract

Background

Hepatitis B virus (HBV) relapse and/or hepatocellular carcinoma (HCC) recurrence remains a major concern for patients who undergo liver transplantation (LT) because of HBV-related HCC. This study investigates the correlation between HBV relapse and HCC recurrence and it explores factors that affect patient outcomes after LT.

Methods

Between September 2002 and August 2009, 78 consecutive patients who underwent LT because of HBV-related HCC were enrolled in this study. Serum samples obtained before LT were assayed both for virological factors associated with HBV DNA and for genotypic characteristics of the virus. All patient clinicopathological features and virological factors were assessed further by univariate and multivariate analyses to determine prognostic factors.

Results

During a median follow-up period of 29.4 months, 13 (16.6 %) patients experienced HCC recurrence and 18 (23.1 %) patients experienced HBV relapse. HBV relapse exhibited a close association with HCC recurrence (p = 0.004) and led to unfavorable overall survival after LT. Multivariate analysis of prognostic factors showed that the basal core promoter (BCP) mutation independently predicted a shorter survival period free from HBV relapse (p = 0.036). Moreover, with the exception of unfavorable tumor characteristics, the BCP mutation was found to be an important prognostic factor that affected HCC recurrence after LT (p = 0.042).

Conclusions

In this study, the HBV–BCP mutation was identified as an important predictor of post-LT clinical outcomes in patients with HBV-related HCC. Therefore, we recommend that aggressive antiviral treatment may be considered for patients associated with this risk factor.

Notes

Acknowledgment

This study was supported by grants from the Chang Gung Medical Research Program (CMRPG370693 and CMRPG3A1392) and from the National Science Council, Taiwan, R.O.C. (NMRP 98-2314-B-182A-048).

Disclosure

All authors declare no conflicts of interest for this study.

Supplementary material

10434_2013_3023_MOESM1_ESM.doc (60 kb)
Supplementary material 1 (DOC 60 kb)
10434_2013_3023_MOESM2_ESM.pptx (2.7 mb)
Supplementary material 2 (PPTX 2774 kb)
10434_2013_3023_MOESM3_ESM.docx (22 kb)
Supplementary material 3 (DOCX 22 kb)

References

  1. 1.
    Yang HI, Sherman M, Su J, et al. Nomograms for risk of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. J Clin Oncol. 2010;28(14):2437–44.PubMedCrossRefGoogle Scholar
  2. 2.
    Dahiya D, Wu TJ, Lee CF, Chan KM, Lee WC, Chen MF. Minor versus major hepatic resection for small hepatocellular carcinoma (HCC) in cirrhotic patients: a 20-year experience. Surgery. 2010;147(5):676–85.PubMedCrossRefGoogle Scholar
  3. 3.
    Lee WC, Jeng LB, Chen MF. Estimation of prognosis after hepatectomy for hepatocellular carcinoma. Br J Surg. 2002;89(3):311–6.PubMedCrossRefGoogle Scholar
  4. 4.
    Wu TJ, Wang F, Lin YS, Chan KM, Yu MC, Lee WC. Right hepatectomy by the anterior method with liver hanging versus conventional approach for large hepatocellular carcinomas. Br J Surg. 2010;97(7):1070–8.PubMedCrossRefGoogle Scholar
  5. 5.
    Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;334(11):693–9.PubMedCrossRefGoogle Scholar
  6. 6.
    Yao FY, Ferrell L, Bass NM, et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology. 2001;33(6):1394–403.PubMedCrossRefGoogle Scholar
  7. 7.
    Terrault N, Roche B, Samuel D. Management of the hepatitis B virus in the liver transplantation setting: a European and an American perspective. Liver Transpl. 2005;11(7):716–32.PubMedCrossRefGoogle Scholar
  8. 8.
    Roche B, Feray C, Gigou M, et al. HBV DNA persistence 10 years after liver transplantation despite successful anti-HBS passive immunoprophylaxis. Hepatology. 2003;38(1):86–95.PubMedCrossRefGoogle Scholar
  9. 9.
    Markowitz JS, Martin P, Conrad AJ, et al. Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin. Hepatology. 1998;28(2):585–9.PubMedCrossRefGoogle Scholar
  10. 10.
    Angus PW, McCaughan GW, Gane EJ, Crawford DH, Harley H. Combination low-dose hepatitis B immune globulin and lamivudine therapy provides effective prophylaxis against posttransplantation hepatitis B. Liver Transpl. 2000;6(4):429–33.PubMedCrossRefGoogle Scholar
  11. 11.
    Han SH, Ofman J, Holt C, et al. An efficacy and cost-effectiveness analysis of combination hepatitis B immune globulin and lamivudine to prevent recurrent hepatitis B after orthotopic liver transplantation compared with hepatitis B immune globulin monotherapy. Liver Transpl. 2000;6(6):741–8.PubMedCrossRefGoogle Scholar
  12. 12.
    Papatheodoridis GV, Sevastianos V, Burroughs AK. Prevention of and treatment for hepatitis B virus infection after liver transplantation in the nucleoside analogues era. Am J Transpl. 2003;3(3):250–8.PubMedCrossRefGoogle Scholar
  13. 13.
    Gane EJ, Angus PW, Strasser S, et al. Lamivudine plus low-dose hepatitis B immunoglobulin to prevent recurrent hepatitis B following liver transplantation. Gastroenterology. 2007;132(3):931–7.PubMedCrossRefGoogle Scholar
  14. 14.
    Wu TJ, Dahiya D, Lee CS, et al. Impact of portal venous hemodynamics on indices of liver function and graft regeneration after right lobe living donor liver transplantation. Liver Transpl. 2011;17(9):1035–45.PubMedGoogle Scholar
  15. 15.
    Bruix J, Sherman M, Llovet JM, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol. 2001;35(3):421–30.PubMedCrossRefGoogle Scholar
  16. 16.
    Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology. 2005;42(5):1208–36.PubMedCrossRefGoogle Scholar
  17. 17.
    Yeh CT, So M, Ng J, et al. Hepatitis B virus-DNA level and basal core promoter A1762T/G1764A mutation in liver tissue independently predict postoperative survival in hepatocellular carcinoma. Hepatology. 2010;52(6):1922–33.PubMedCrossRefGoogle Scholar
  18. 18.
    Wu TJ, Chen TC, Wang F, et al. Large fragment pre-s deletion and high viral load independently predict hepatitis B relapse after liver transplantation. PLoS One. 2012;7(2):e32189.PubMedCrossRefGoogle Scholar
  19. 19.
    Faria LC, Gigou M, Roque-Afonso AM, et al. Hepatocellular carcinoma is associated with an increased risk of hepatitis B virus recurrence after liver transplantation. Gastroenterology. 2008;134(7):1890–9.PubMedCrossRefGoogle Scholar
  20. 20.
    Saab S, Yeganeh M, Nguyen K, et al. Recurrence of hepatocellular carcinoma and hepatitis B reinfection in hepatitis B surface antigen-positive patients after liver transplantation. Liver Transpl. 2009;15(11):1525–34.PubMedCrossRefGoogle Scholar
  21. 21.
    Chun J, Kim W, Kim BG, et al. High viremia, prolonged Lamivudine therapy and recurrent hepatocellular carcinoma predict posttransplant hepatitis B recurrence. Am J Transpl. 2010;10(7):1649–59.PubMedCrossRefGoogle Scholar
  22. 22.
    Locarnini S, McMillan J, Bartholomeusz A. The hepatitis B virus and common mutants. Semin Liver Dis. 2003;23(1):5–20.PubMedCrossRefGoogle Scholar
  23. 23.
    Chen CH, Hung CH, Lee CM, et al. Pre-S deletion and complex mutations of hepatitis B virus related to advanced liver disease in HBeAg-negative patients. Gastroenterology. 2007;133(5):1466–74.PubMedCrossRefGoogle Scholar
  24. 24.
    Grottola A, Buttafoco P, Del Buono MG, et al. Pretransplantation pre-S2 and S protein heterogeneity predisposes to hepatitis B virus recurrence after liver transplantation. Liver Transpl. 2002;8(5):443–8.PubMedCrossRefGoogle Scholar
  25. 25.
    Gaglio P, Singh S, Degertekin B, et al. Impact of the hepatitis B virus genotype on pre- and post-liver transplantation outcomes. Liver Transpl. 2008;14(10):1420–7.PubMedCrossRefGoogle Scholar
  26. 26.
    Liu S, Zhang H, Gu C, et al. Associations between hepatitis B virus mutations and the risk of hepatocellular carcinoma: a meta-analysis. J Natl Cancer Inst. 2009;101(15):1066–82.PubMedCrossRefGoogle Scholar
  27. 27.
    Woo HY, Choi JY, Jang JW, et al. Role of long-term lamivudine treatment of hepatitis B virus recurrence after liver transplantation. J Med Virol. 2008;80(11):1891–9.PubMedCrossRefGoogle Scholar
  28. 28.
    Angus PW, Patterson SJ. Liver transplantation for hepatitis B: what is the best hepatitis B immune globulin/antiviral regimen? Liver Transpl. 2008;14(Suppl 2):S15–22.PubMedCrossRefGoogle Scholar
  29. 29.
    Lake JR. Do we really need long-term hepatitis B hyperimmune globulin? What are the alternatives? Liver Transpl. 2008;14(Suppl 2):S23–6.PubMedCrossRefGoogle Scholar
  30. 30.
    Nath DS, Kalis A, Nelson S, Payne WD, Lake JR, Humar A. Hepatitis B prophylaxis post-liver transplant without maintenance hepatitis B immunoglobulin therapy. Clin Transpl. 2006;20(2):206–10.PubMedCrossRefGoogle Scholar
  31. 31.
    Jonas S, Bechstein WO, Steinmuller T, et al. Vascular invasion and histopathologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis. Hepatology. 2001;33(5):1080–6.PubMedCrossRefGoogle Scholar
  32. 32.
    Mazzaferro V, Chun YS, Poon RT, et al. Liver transplantation for hepatocellular carcinoma. Ann Surg Oncol. 2008;15(4):1001–7.PubMedCrossRefGoogle Scholar
  33. 33.
    Chan KM, Chou HS, Wu TJ, Lee CF, Yu MC, Lee WC. Characterization of hepatocellular carcinoma recurrence after liver transplantation: perioperative prognostic factors, patterns, and outcome. Asian J Surg. 2011;34(3):128–34.PubMedCrossRefGoogle Scholar
  34. 34.
    Dong Q, Chan HL, Liu Z, et al. A1762T/G1764A mutations of hepatitis B virus, associated with the increased risk of hepatocellular carcinoma, reduce basal core promoter activities. Biochem Biophys Res Commun. 2008;374(4):773–6.PubMedCrossRefGoogle Scholar
  35. 35.
    Huang Y, Tong S, Tai AW, Hussain M, Lok AS. Hepatitis B virus core promoter mutations contribute to hepatocarcinogenesis by deregulating SKP2 and its target, p21. Gastroenterology. 2011;141(4):1412–21.PubMedCrossRefGoogle Scholar

Copyright information

© Society of Surgical Oncology 2013

Authors and Affiliations

  • Ting-Jung Wu
    • 1
    • 4
  • Kun-Ming Chan
    • 1
  • Hong-Shiue Chou
    • 1
  • Chen-Fang Lee
    • 1
  • Tsung-Han Wu
    • 1
  • Tse-Ching Chen
    • 2
  • Chau-Ting Yeh
    • 3
  • Wei-Chen Lee
    • 1
  1. 1.Chang Gung Transplantation InstituteChang Gung Memorial Hospital at Linkou, Chang Gung University College of MedicineTaoyuanTaiwan
  2. 2.Department of PathologyChang Gung Memorial Hospital at Linkou, Chang Gung University College of MedicineTaoyuanTaiwan
  3. 3.Department of Hepato-Gastroenterology, Liver Research Center, Chang Gung Memorial Hospital at LinkouChang Gung University College of MedicineTaoyuanTaiwan
  4. 4.Graduate Institute of Clinical Medical SciencesChang Gung University College of MedicineTaoyuanTaiwan

Personalised recommendations